News

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug
Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable ...
U.S. approves first-ever biannual shot to prevent HIV, but getting it might be hard
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...
Metro Weekly17h
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection
He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...
KESQ1d
FDA approves twice-yearly HIV prevention shot amid questions over cost, access
The U.S. Food and Drug Administration has approved a groundbreaking HIV prevention shot that only needs to be taken twice a year. Medical experts are calling it one of the most significant ...
WDAM1d
FDA approves twice-yearly injectable for HIV prevention; local agency weighs in on impact in the Pine Belt
PINE BELT, Miss. (WDAM) - The medical community has reached another milestone that could put an end to the decades-long HIV epidemic. The Food & Drug Administration approved Yeztugo (Lenacapavir) ...
American Hospital Association1d
FDA approves first semiannual HIV prevention drug
The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...
MPR1d
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
The American Journal of Managed Care1d
Cost Will Be Massive Barrier in Access to Lenacapavir After Approval in the US: Gordon Crofoot, MD, PA
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.
2 East Bay drugmaking sites sold to Indian manufacturer
How an Indian contract manufacturer will establish a biotech foothold in the U.S.